Ali Aminian1, Stacy A Brethauer, Amin Andalib, Amy S Nowacki, Amanda Jimenez, Ricard Corcelles, Zubaidah Nor Hanipah, Suriya Punchai, Deepak L Bhatt, Sangeeta R Kashyap, Bartolome Burguera, Antonio M Lacy, Josep Vidal, Philip R Schauer. 1. *Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, OH †Center for Bariatric Surgery, McGill University, Montreal, QC, Canada ‡Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH §Hospital Clínic Universitari, Barcelona, Spain ¶Department of Surgery, University Putra Malaysia, Selangor, Malaysia ||Department of Surgery, Khon Kaen University, Khon Kaen, Thailand **Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA ††Endocrine and Metabolic Institute, Cleveland Clinic, Cleveland, OH ‡‡CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain.
Abstract
OBJECTIVE: To construct and validate a scoring system for evidence-based selection of bariatric and metabolic surgery procedures according to severity of type 2 diabetes (T2DM). BACKGROUND: Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) account for >95% of bariatric procedures in United States in patients with T2DM. To date, there is no validated model to guide procedure selection based on long-term glucose control in patients with T2DM. METHODS: A total of 659 patients with T2DM who underwent RYGB and SG at an academic center in the United States and had a minimum 5-year follow-up (2005-2011) were analyzed to generate the model. The validation dataset consisted of 241 patients from an academic center in Spain where similar criteria were applied. RESULTS: At median postoperative follow-up of 7 years (range 5-12), diabetes remission (HbA1C <6.5% off medications) was observed in 49% after RYGB and 28% after SG (P < 0.001). Four independent predictors of long-term remission including preoperative duration of T2DM (P < 0.0001), preoperative number of diabetes medications (P < 0.0001), insulin use (P = 0.002), and glycemic control (HbA1C < 7%) (P = 0.002) were used to develop the Individualized Metabolic Surgery (IMS) score using a nomogram. Patients were then categorized into 3 stages of diabetes severity. In mild T2DM (IMS score ≤25), both procedures significantly improved T2DM. In severe T2DM (IMS score >95), when clinical features suggest limited functional β-cell reserve, both procedures had similarly low efficacy for diabetes remission. There was an intermediate group, however, in which RYGB was significantly more effective than SG, likely related to its more pronounced neurohormonal effects. Findings were externally validated and procedure recommendations for each severity stage were provided. CONCLUSIONS: This is the largest reported cohort (n = 900) with long-term postoperative glycemic follow-up, which, for the first time, categorizes T2DM into 3 validated severity stages for evidence-based procedure selection.
OBJECTIVE: To construct and validate a scoring system for evidence-based selection of bariatric and metabolic surgery procedures according to severity of type 2 diabetes (T2DM). BACKGROUND: Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) account for >95% of bariatric procedures in United States in patients with T2DM. To date, there is no validated model to guide procedure selection based on long-term glucose control in patients with T2DM. METHODS: A total of 659 patients with T2DM who underwent RYGB and SG at an academic center in the United States and had a minimum 5-year follow-up (2005-2011) were analyzed to generate the model. The validation dataset consisted of 241 patients from an academic center in Spain where similar criteria were applied. RESULTS: At median postoperative follow-up of 7 years (range 5-12), diabetes remission (HbA1C <6.5% off medications) was observed in 49% after RYGB and 28% after SG (P < 0.001). Four independent predictors of long-term remission including preoperative duration of T2DM (P < 0.0001), preoperative number of diabetes medications (P < 0.0001), insulin use (P = 0.002), and glycemic control (HbA1C < 7%) (P = 0.002) were used to develop the Individualized Metabolic Surgery (IMS) score using a nomogram. Patients were then categorized into 3 stages of diabetes severity. In mild T2DM (IMS score ≤25), both procedures significantly improved T2DM. In severe T2DM (IMS score >95), when clinical features suggest limited functional β-cell reserve, both procedures had similarly low efficacy for diabetes remission. There was an intermediate group, however, in which RYGB was significantly more effective than SG, likely related to its more pronounced neurohormonal effects. Findings were externally validated and procedure recommendations for each severity stage were provided. CONCLUSIONS: This is the largest reported cohort (n = 900) with long-term postoperative glycemic follow-up, which, for the first time, categorizes T2DM into 3 validated severity stages for evidence-based procedure selection.
Authors: Jerry T. Dang; Caroline Sheppard; David Kim; Noah Switzer; Xinzhe Shi; Chunhong Tian; Christopher de Gara; Shahzeer Karmali; Daniel W. Birch Journal: Can J Surg Date: 2019-10-01 Impact factor: 2.089
Authors: Julian Bühler; Silvan Rast; Christoph Beglinger; Ralph Peterli; Thomas Peters; Martina Gebhart; Anne Christin Meyer-Gerspach; Bettina Karin Wölnerhanssen Journal: Obes Facts Date: 2020-12-17 Impact factor: 3.942
Authors: Zubaidah Nor Hanipah; Suriya Punchai; Linden A Karas; Samuel Szomstein; Rahul J Rosenthal; Stacy A Brethauer; Ali Aminian; Philip R Schauer Journal: Obes Surg Date: 2018-06 Impact factor: 4.129